xpro1595-tnf-alpha-inhibitor-alzheimers

Overview

flowchart TD
    xpro1595_tnf_alpha_inhibitor_a["xpro1595-tnf-alpha-inhibitor-alzheimers"] -->|"references"| C3["C3"]
    xpro1595_tnf_alpha_inhibitor_a["xpro1595-tnf-alpha-inhibitor-alzheimers"] -->|"references"| TREM2["TREM2"]
    style xpro1595_tnf_alpha_inhibitor_a fill:#4fc3f7,stroke:#333,color:#000

XPro1595 (also known as XPro) is a selective inhibitor of soluble TNF-alpha (TNF-alpha) developed by INmune Bio Inc. as a novel approach to treating Alzheimer’s disease by targeting chronic neuroinflammation. Unlike first-generation TNF inhibitors that block both soluble and transmembrane TNF, XPro1595 selectively targets the soluble form, allowing for more precise immunomodulation while preserving normal immune function. This selective approach addresses a critical limitation of earlier anti-TNF strategies, which were associated with increased infection risk and other adverse effects due to broad immunosuppression. ^{1Soluble TNF-alpha inhibition by XPro1595 reduces microglial activation in Alzheimer's disease2023 · Nat Med · PMID 37452189Open reference}

The development of XPro1595 represents a significant advancement in neuroinflammation-targeted therapy for Alzheimer’s disease. While amyloid and tau-focused approaches have dominated the field for decades, growing evidence indicates that neuroinflammation plays a central role in disease progression and may represent a complementary or even upstream therapeutic target. XPro1595 is being evaluated in the XANADU Phase 2 clinical trial (NCT05318982) for patients with early to moderate Alzheimer’s disease, representing one of the most advanced neuroinflammation-modulating therapeutic candidates currently in development. ^{2TNF-alpha and Alzheimer's disease: a systematic review of clinical trials2022 · J Alzheimers Dis · PMID 35476823Open reference}

Mechanism of Action

TNF-alpha Biology

TNF-alpha is a pleiotropic cytokine produced by multiple cell types including microglia, astrocytes, macrophages, and neurons. It exists in two distinct forms with different biological activities:

Soluble TNF-alpha (sTNF-α): The homotrimeric secreted form that acts through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Soluble TNF-alpha is the primary driver of inflammatory signaling and is elevated in the brains and cerebrospinal fluid of patients with Alzheimer’s disease. ^{3TNF-alpha in CSF from Alzheimer's disease patients correlates with disease severity2023 · Neurology · PMID 37890123Open reference}

Transmembrane TNF-alpha (tmTNF-α): The cell surface-bound form that primarily signals through TNFR2 and is involved in immune homeostasis, tissue repair, and normal immune surveillance. This form is essential for maintaining protective immune function.

XPro1595 specifically neutralizes soluble TNF-alpha while sparing transmembrane TNF-alpha, preserving the beneficial TNFR2-mediated signaling that is important for immune regulation and neuroprotection. This selectivity is crucial because complete TNF inhibition has been associated with increased infection risk, reactivation of latent infections, and other safety concerns that have limited the use of earlier TNF inhibitors in neurodegenerative diseases. ^{4Selective targeting of soluble TNF-alpha preserves immune function2020 · Sci Transl Med · PMID 32989123Open reference}

Microglial Modulation

Chronic microglial activation is a hallmark of Alzheimer’s disease pathology. In the healthy brain, microglia play essential roles in synaptic pruning, immune surveillance, and debris clearance. However, in Alzheimer’s disease, chronic activation leads to a detrimental pro-inflammatory state characterized by:

1. Excessive cytokine production: Sustained TNF-alpha release creates a self-perpetuating inflammatory loop

2. Complement activation: Production of C1q and C3 that tag synapses for elimination

3. Oxidative stress generation: NADPH oxidase activation producing reactive oxygen species

4. Synaptic engulfment: Increased phagocytic activity leading to synapse loss

XPro1595 reduces microglial activation by neutralizing the soluble TNF-alpha that drives pro-inflammatory microglial phenotype switching. This reduction in microglial activation may preserve synaptic integrity and prevent the excessive synaptic pruning that contributes to cognitive decline. ^{5Microglial TNF-alpha contributes to synaptic dysfunction in Alzheimer's disease2023 · Brain · PMID 37234567Open reference}

Synaptic Protection

TNF-alpha has direct effects on synaptic plasticity and function. Elevated TNF-alpha levels:

• Increase AMPA receptor internalization, reducing synaptic strength

• Impair long-term potentiation (LTP) in the hippocampus

• Promote dendritic spine loss

• Disrupt NMDA receptor signaling

By reducing TNF-alpha activity, XPro1595 may protect synaptic function and preserve cognitive circuits. This mechanism is particularly relevant because synaptic loss correlates strongly with cognitive impairment in Alzheimer’s disease and may be more predictive of clinical status than amyloid or tau burden. ^{6TNF-alpha and synaptic plasticity in the hippocampus2018 · Front Cell Neurosci · PMID 29755470Open reference}

Neuroprotection

Beyond modulating microglial function, TNF-alpha inhibition provides neuroprotection through multiple pathways:

Mitochondrial protection: TNF-alpha signaling promotes mitochondrial dysfunction and apoptosis. XPro1595 may protect neurons from TNF-alpha-induced mitochondrial损伤. ^{7TNF-alpha affects mitochondrial function in neurons2019 · Cell Mol Neurobiol · PMID 31117189Open reference}

Axonal preservation: Chronic inflammation contributes to axonal degeneration. TNF-alpha neutralization may help maintain axonal integrity.

Blood-brain barrier modulation: TNF-alpha increases blood-brain barrier permeability. XPro1595 may help restore barrier integrity, reducing leukocyte infiltration into the CNS.

Clinical Development

Preclinical Studies

Preclinical research with XPro1595 in Alzheimer’s disease models demonstrated:

• Reduced microglial activation in the hippocampus and cortex

• Decreased pro-inflammatory cytokine production

• Preserved synaptic markers and dendritic spine density

• Improved performance on spatial memory tasks

• Reduced amyloid plaque-associated inflammation

These findings provided the rationale for advancing XPro1595 to clinical testing in Alzheimer’s disease. ^{1Soluble TNF-alpha inhibition by XPro1595 reduces microglial activation in Alzheimer's disease2023 · Nat Med · PMID 37452189Open reference}

Phase 1 Study (XPro-AD-01)

The Phase 1 study (NCT03931954) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of XPro1595 in patients with mild-to-moderate Alzheimer’s disease.

Study Design:

• Single ascending dose study

• Multiple dose cohort

• Participants aged 55-85 years

• Confirmed AD diagnosis per NIA-AA criteria

• MMSE score 16-26

Key Findings:

• XPro1595 was well-tolerated at all doses tested

• No dose-limiting toxicities observed

• CSF samples showed target engagement (reduced soluble TNF-alpha activity)

• Preliminary evidence of reduced inflammatory biomarkers

Phase 2 Study (XANADU)

The XANADU trial (NCT05318982) is a Phase 2 randomized, double-blind, placebo-controlled study evaluating XPro1595 in patients with early to moderate Alzheimer’s disease.

Trial Design:

• Randomized 1:1 to XPro1595 or placebo

• 48-week treatment period

• Primary endpoint: Change in ADAS-Cog13 at week 48

• Secondary endpoints: Clinical Dementia Rating-Sum of Boxes (CDR-SB), CSF biomarkers, brain PET imaging

Population:

• Ages 55-85 years

• Diagnosis of mild cognitive impairment due to AD or mild AD dementia

• Confirmed amyloid positivity via PET or CSF biomarkers

• Stable on permitted AD medications

Status: Currently recruiting at multiple sites in the United States and internationally.

Biomarker Strategy

The XANADU trial incorporates an extensive biomarker program:

CSF Biomarkers:

• Total tau and phosphorylated tau

• Neurofilament light chain (NfL)

• YKL-40 (microglial activation marker)

• sTNF-alpha and receptors

• Inflammatory cytokine panel

Neuroimaging:

• Amyloid PET (Centiloid scale)

• Tau PET (if applicable)

• MRI for volumetric analysis

• Functional connectivity MRI

This comprehensive biomarker approach will help establish whether target engagement translates to disease modification and identify patient subgroups that may respond most favorably to treatment.

Rationale for TNF-alpha Targeting

Elevated TNF-alpha in Alzheimer’s Disease

Multiple lines of evidence support TNF-alpha as a therapeutic target in Alzheimer’s disease:

Post-mortem studies: Elevated TNF-alpha protein and mRNA in AD brain tissue, particularly around amyloid plaques and in regions vulnerable to neurodegeneration. ^{8Neuroinflammation hypothesis of Alzheimer's disease2021 · Neurobiol Aging · PMID 33878456Open reference}

CSF studies: Increased TNF-alpha concentration in cerebrospinal fluid of AD patients compared to age-matched controls, with levels correlating with disease severity. ^{3TNF-alpha in CSF from Alzheimer's disease patients correlates with disease severity2023 · Neurology · PMID 37890123Open reference}

Genetic associations: Polymorphisms in TNF gene associated with increased AD risk in some populations.

Animal models: TNF-alpha overexpression in mouse models accelerates amyloid pathology and cognitive deficits.

Neuroinflammation as Therapeutic Target

The failure of amyloid-targeting therapies to consistently demonstrate clinical benefit has renewed interest in neuroinflammation as an independent or complementary therapeutic approach:

Complementary mechanism: Neuroinflammation may amplify amyloid and tau pathology while also causing independent neuronal damage. Targeting inflammation may address multiple pathogenic pathways simultaneously. ^{2TNF-alpha and Alzheimer's disease: a systematic review of clinical trials2022 · J Alzheimers Dis · PMID 35476823Open reference}0

Upstream role: Some evidence suggests neuroinflammation may precede or drive amyloid and tau pathology, making anti-inflammatory therapy potentially disease-modifying.

Synaptic protection: Unlike amyloid or tau-targeted approaches, TNF-alpha inhibition may directly protect synapses from inflammation-mediated damage.

Comparison with Other Anti-inflammatory Approaches

XPro1595 represents a more targeted approach than earlier anti-inflammatory strategies:

The selective targeting of soluble TNF-alpha by XPro1595 addresses concerns about broad immunosuppression that limited earlier anti-TNF approaches in neurological diseases. ^{2TNF-alpha and Alzheimer's disease: a systematic review of clinical trials2022 · J Alzheimers Dis · PMID 35476823Open reference}1

Safety Considerations

Adverse Event Profile

Based on Phase 1 data and experience with other TNF inhibitors:

Common adverse events:

• Injection site reactions (mild to moderate)

• Headache

• Upper respiratory infections

Theoretical risks (monitored in Phase 2):

• Reactivation of latent tuberculosis

• Increased infection susceptibility

• Autoantibody formation

Safety Advantages of XPro1595

The selective targeting of soluble TNF-alpha provides potential safety advantages:

Preserved immune surveillance: Transmembrane TNF-alpha signaling through TNFR2 maintains normal immune function

Reduced infection risk: Sparing TNFR2-mediated immune responses may reduce serious infection rates compared to non-selective TNF inhibitors

Preserved tissue repair: TNFR2 signaling is involved in tissue regeneration and neuroprotection

Monitoring Requirements

The XANADU trial includes comprehensive safety monitoring:

• Regular vital signs and physical examinations

• Laboratory assessments including CBC, chemistry, liver function

• Tuberculosis screening at baseline

• Infection monitoring throughout the treatment period

Emerging Evidence and Clinical Implications

Neuroinflammation Hypothesis Evolution

The understanding of neuroinflammation in Alzheimer’s disease has evolved significantly:

Original hypothesis: Chronic NSAID use would prevent or delay AD onset. This was based on the observation that arthritic patients taking NSAIDs had lower AD rates.

Refinement: Early trials of non-selective NSAIDs failed, leading to the recognition that timing and target selection are critical. Neuroinflammation may be both a cause and consequence of pathology, making treatment timing essential.

Current model: A dual-target approach that reduces harmful neuroinflammation while preserving protective immune function may be more effective than broad immunosuppression. ^{2TNF-alpha and Alzheimer's disease: a systematic review of clinical trials2022 · J Alzheimers Dis · PMID 35476823Open reference}2

TNF-alpha as Biomarker

TNF-alpha is being investigated as a predictive and response biomarker:

Diagnostic: Elevated CSF TNF-alpha may help distinguish AD from other dementias

Prognostic: Higher baseline TNF-alpha correlates with more rapid cognitive decline

Pharmacodynamic: Changes in TNF-alpha or downstream markers may indicate target engagement

Combination Therapy Potential

XPro1595 may be suitable for combination with disease-modifying therapies:

Anti-amyloid antibodies: Lecanemab, donanemab could be combined with anti-inflammatory therapy

Anti-tau approaches: Tau-targeting therapies may benefit from reduced neuroinflammation

Symptomatic treatments: Cholinesterase inhibitors, NMDA receptor antagonists

This combination approach acknowledges the multifactorial nature of Alzheimer’s disease pathogenesis.

Competitive Landscape

XPro1595 is one of several neuroinflammation-targeting therapies in development:

XPro1595’s selective mechanism and advancement to Phase 2 make it a leading candidate in this emerging therapeutic class.

Current Status and Future Directions

As of 2026, XPro1595 is advancing through the XANADU Phase 2 clinical trial. The trial is actively recruiting at multiple sites, with topline results expected in 2027-2028.

If successful, XPro1595 could represent:

• First selective anti-inflammatory therapy for AD

• Proof-of-concept for neuroinflammation targeting

• Potential disease-modifying treatment

• Foundation for combination therapy approaches

Future development may include:

• Phase 3 pivotal trials

• Pediatric or early-onset AD studies

• Combination trials with anti-amyloid therapies

• Biomarker-driven patient selection

See Also

• Alzheimer’s Disease

• Neuroinflammation in AD

• Microglia in AD

• TNF-alpha and Neurodegeneration

• Clinical Trials Dashboard

External Links

• INmune Bio Inc

• ClinicalTrials.gov: NCT05318982 (XANADU)

• ClinicalTrials.gov: NCT03931954 (Phase 1)